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Influenza A virus (IAV) matrix protein 2 (M2), an ion channel, is crucial for virus infection,
and therefore, an important anti-influenza drug target. Adamantanes, also known as
M2 channel blockers, are one of the two classes of Food and Drug Administration-
approved anti-influenza drugs, although their use was discontinued due to prevalent
drug resistance. Fast emergence of resistance to current anti-influenza drugs have
raised an urgent need for developing new anti-influenza drugs against resistant forms
of circulating viruses. Here we propose a simple theoretical criterion for fast virtual
screening of molecular libraries for candidate anti-influenza ion channel inhibitors both
for wild type and adamantane-resistant influenza A viruses. After in silico screening of
drug space using the EIIP/AQVN filter and further filtering of drugs by ligand based virtual
screening and molecular docking we propose the best candidate drugs as potential dual
inhibitors of wild type and adamantane-resistant influenza A viruses. Finally, guanethidine,
the best ranked drug selected from ligand-based virtual screening, was experimentally
tested. The experimental results show measurable anti-influenza activity of guanethidine
in cell culture.
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INTRODUCTION
Influenza is a serious global public health concern. Regardless of the availability of antiviral drugs
and vaccines, according to the World Health Organization’s estimates, influenza is the cause of 3 to
5 million cases of severe illness and about 290,000–650,000 deaths in seasonal outbreaks worldwide
(WHO Influenza, 2018). Annual “flu” vaccination has a primary role in preventing influenza A and
B virus infections and increasing population immunity even though the efficacy of the seasonal
flu vaccines may vary from year to year (Bridges et al., 2013). Since the current flu vaccination
approach is imperfect, a substantial portion of the population is susceptible to infection even
after vaccination every year. Therefore, alternative strategies should be considered to improve our
therapeutic abilities for those patients that develop clinical flu. This would be especially important
in the pandemic setting with rapid virus transmission due to the currently limited ability for fast,
new vaccine production (Bridges et al., 2013). Current treatment and prophylaxis against seasonal
influenza is limited to the only licensed class of antivirals, namely neuraminidase inhibitors (NAIs).
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Oseltamivir and zanamivir are currently licensed worldwide
while peramivir and laninamivir are approved in some countries
(Ison, 2017). The frequency of NAI resistance in currently
circulating strains is low, <1% (Hurt et al., 2016), but resistance
to oseltamivir, the most widely used NAI, was extensive amongst
former seasonal H1N1 viruses in 2008. (Hurt et al., 2009),
and was detected in localized clusters of oseltamivir-resistant
H1N1pdm09 (Hurt et al., 2011). Nevertheless, the therapeutic
window for treatment with these drugs is very short and patients
benefit the most when treated 24–48 h after the onset of “flu”
symptoms (Ison, 2017).
The first of the two classes of FDA-approved anti-influenza
drugs are adamantanes, amantadine and rimantadine, that
inhibit viral replication by blocking the wild-type (WT) M2
proton channel.
IAV matrix protein 2 (M2), an ion channel protein, is
one of the most conserved viral proteins and essential for
efficient virus replication, and is thus an important anti-influenza
drug target (Takeda et al., 2002). Matrix protein 2 (M2) is a
97-residue-long viral protein that encompasses a 19-residue-
long hydrophobic transmembrane domain (TM) that forms a
homotetrameric proton-selective channel involved in proton
conductance and drug binding (Lamb et al., 1985; Sakaguchi
et al., 1997). Adamantanes have been used successfully against
influenza A virus infection formore than 30 years because of their
wide accessibility and low price (Dolin et al., 1982). However,
as a consequence of the lack of activity against influenza B
(Mould et al., 2003), adverse effects, and the rapid emergence of
resistance during treatment or even in the absence of selective
drug pressure, the Centers for Disease Control and Prevention
(CDC) have strongly recommended against the use of this class
of drugs (CDC, 2006). The molecular basis for resistance to
adamantanes is connected with several amino acid substitutions
and the M2-S31N variant is found in more than 95% of the
currently circulating influenza A viruses (Dong et al., 2015).
The expansion of M2 viruses with S31N mutation in the early
2000s is not a consequence of drug selection pressure but is
connected to advantageous substitutions elsewhere in the virus,
in a process denoted as genetic “hitch-hiking” (Simonsen et al.,
2007). On the other hand, the latest report of M2 S31 and
D31 viruses in Australia suggests that the role of the M2 N31
residue in viral fitness is no longer as important as it used to be
(Hurt et al., 2017). Considering all these facts, new effective anti-
influenza M2 inhibitors that target both WT and S31N mutant
are greatly needed. Several high-resolution M2 structures that
provide important insights into the favorable structural features
can be employed for designing new M2 inhibitors (Hong and
DeGrado, 2012).
A recent, and very popular drug discovery approach—drug
repurposing (DR), wherein old drugs are given new indication by
exploring new molecular pathways and targets for intervention
(Strittmatter, 2014)- offers potential economic advantage and
shorter regulatory process for the clinical approval. The
continuous increase of drug-resistant pathogens is a great
challenge for treatment of infectious diseases and DR serves
as an alternative approach for rapid identification of effective
therapeutics (Zheng et al., 2018). Drug repurposing (DR) applied
to viral infectious diseases integrates both screening of bioactive
small-molecule collections and computational methods to find a
molecule, a pathway, or a biological activity that could be used
against the virus of interest (Mercorelli et al., 2018). Two clinical
trials against influenza viruses with repositioned drugs are
currently underway: (1) The first trial (phase 2b/3clinical trial)
combines clarithromycin and naproxen along with oseltamivir
in a triple-drug combination and; (2) the second trial is focused
on testing efficacy of an antiparasitic drug, nitazoxanide, against
influenza viruses (Phase III) (Mercorelli et al., 2018).
In this study we propose a simple theoretical criterion
for fast virtual screening of molecular libraries for candidate
anti-influenza M2 ion channel inhibitors both for wild type
and adamantane-resistant influenza A viruses. After in silico
screening of drug space using the EIIP/AQVN filter, and further
filtering of drugs by ligand based virtual screening and molecular
docking, we proposed the five best candidate drugs as potential
dual inhibitors of wild type and adamantane-resistant influenza
A viruses.
MATERIALS AND METHODS
For screening of drugs for repurposing to select candidates for
influenza M2 inhibitors, 2,627 approved small molecule drugs
from DrugBank (http://www.drugbank.ca) were screened. To
define the predictive criterion for the selection of Influenza
M2 candidates, the learning set (Supplementary Tables 1,
2) was composed of all active compounds from ChEMBL
Target Report Card (https://www.ebi.ac.uk/chembl/target/
inspect/CHEMBL613740) (EMBL-EBI. ChEMBL). (EMBL-EBI.
ChEMBL. Available online: https://www.ebi.ac.uk/chembl/
(accessed on June 30, 2018) against influenza A virus M2
(Target ID CHEMBL613740) both for wild type (WT) and
S31N, with corresponding IC50 values. The total number of
reported compounds for WT and S39N of M2 channel were 50
and 49, respectively. After removal of duplicates and inactive
compounds, the final number of compounds was 15 for WT
and 12 for the S31N mutant (Supplementary Tables 1, 2). The
control data sets were compounds from PubChem compounds
database (http://www.ncbi.nlm.nih.gov/pccompound).
Virtual Screening
The virtual screening (VS) protocol included the application of
subsequent filters to select candidate dual inhibitors of M2 ion
channel. The first EIIP/AQVN filter approach was employed for
in silico screening of the ChEMBL Target Report Card (https://
www.ebi.ac.uk/chembl/target/inspect/CHEMBL613740) and
DrugBank (http://www.drugbank.ca) (Wishart et al., 2006) and
then proceeded by ligand-based screening.
EIIP/AQVN
The EIIP for organic molecules can be determined by the
following simple equation derived from the “general model
pseudopotential (Veljkovic et al., 2011).
EIIP = 0.25Z∗sin(1.04piZ∗)/2pi (1)
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Where Zi is the valence number of the ith atomic component, ni
is the number of atoms of the ith component,m is the number of
atomic components in the molecule, and N is the total number
of atoms. EIIP values calculated according to Equations (1, 2) are
expressed in Rydberg units (Ry).
Ligand-Based Virtual Screening
To screen selected compounds from Drugbank, both learning
set compounds and candidates from the previous step were
converted to 3D sdf format from smiles. GRIND descriptors of
molecules were calculated, based on molecular interaction field
(MIF) probes (Duran et al., 2009). Computation method for
descriptor generation was GRID with step 0.5. Applied probes
(mapped regions of molecule surface) were DRY (hydrophobic
interactions) O (hydrogen bond acceptor) N1 (hydrogen bond
donor) and TIP (molecular shape descriptor). Discretization
Method was AMANDA (Duran et al., 2008), with scale factor
0.55. Cut off was set to: DRY −0.5 O −2.6 N1 −4.2 TIP −0.75.
Encoding Method was MACC2 and weights were the following:
DRY: −0.5, O: −2.6, N1: −4.2, TIP: −0.75. Number of PCA
components was set to five. Explained variance of such obtained
model was 58.84%. Then, learning set compounds were imported
and served for screening the candidate compound database. All
calculations were carried in Pentacle software version 1.06 for
Linux (Pastor et al., 2000).
FIGURE 1 | Schematic presentation of the EIIP/AQVN criterion for selection of
candidate M2 inhibitors. Common domain of active compounds for both WT
and S31N M2 (red) with AQVN (2.21–2.32), EIIP (0.071–0.089). Chemical
space (blue) with AQVN (2.40–3.30) EIIP (0.000–0.116)—EIIP/AQVN domain




Crystal structures of the wild type M2 channel and the S31N
mutant channel were downloaded from RCSB PDB database
(https://www.rcsb.org/) with PDBIDs 2KQT (Cady et al., 2010)
and 2LY0 (Wang et al., 2013) respectively. All ligands, ions and
water molecules were removed from structures. All hydrogen
atoms were added on protein structures and then truncated to
only polar hydrogen atoms during the preparation process. The
receptor was prepared in ADT Tools 1.5.6 (Sanner, 1999; Morris
et al., 2009).
Ligand Preparation
Ligands were converted from 3Dsdf tomol2 format and imported
to Avogadro software in order to protonate them at physiological
pH. Molecules were prepared for MOPAC 2016 (Stewart, 2016)
and geometrically optimized on PM7 (Stewart, 2013) level of
theory. They were further prepared for molecular docking in
ADT Tools.
Molecular Docking
A grid box with dimensions 24 × 24 × 24A was placed in the
center of the binding site of the protein receptor. Exhaustiveness
was set to 50. Molecular docking was carried in Autodock Vina
(Trott and Olson, 2010).
In vitro Efficacy Testing of Guanethidine
Against Influenza a (h1n1) Virus
Influenza A/CA/07/2009 (H1N1) virus was premixed with 1,
10, and 100µM of guanethidine and incubated at 37C for 1
hr. Positive control wells were prepared by mixing influenza
A/CA/07/2009 (H1N1) virus with 10µM of merimepodib.
MDCK cells were then infected in triplicates with influenza
A/CA/07/2009 (H1N1) virus / drug mixture. After ∼1 h of
incubation at 37◦C and 5% CO2, cells were washed with serum
free media and 1× of each compound dose was added to the
cells. Virus control wells as well as untreated control wells were
included in triplicates. Cells were incubated at 37C and 5% CO2
and samples were collected at 0, 1, 2, and 3 days post-infection.
Samples were stored at −80◦C until the day of analysis. The
influenza virus titer in MDCK cells via TCID50 was performed
for each sample collected at days 0, 1, and 2 post-infection.
RESULTS
The virtual screening (VS) protocol in this study was based
on the application of sequential filters to select candidate dual
inhibitors of the M2 ion channel. Previously it was shown
for molecular targets in diverse pathological states that small
molecules with similar AQVN and EIIP values interact with
the common therapeutic targets (Veljkovic et al., 2011, 2013).
This resulted in determining criteria for virtual screening of
molecular libraries for compounds with similar therapeutic
properties (Veljkovic et al., 2013). The learning set consists
of M2 WT (Supplementary Table 1), and M2 S31N mutant
(Supplementary Table 2) ion channel inhibitors from the
ChEMBL Target Report Card (https://www.ebi.ac.uk/chembl/
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TABLE 1 | Approved drugs screened for candidate anti-M2 inhibitors.
Drugbank accession number Name Chemical formula AQVN EIIP
DB00915 Amantadine C10H17N 2.214286 0.071739
DB06689 Ethanolamine Oleate C18H34O2.C2H7NO 2.215385 0.071958
DB00153 Ergocalciferol C28H44O 2.219178 0.072708
DB00898 Ethanol C2H6O 2.222222 0.073303
DB01105 Sibutramine C17H26ClN 2.222222 0.073303
DB01158 Bretylium C11H17BrN 2.233333 0.075425
DB00804 Dicyclomine C19H35NO2 2.245614 0.077673
DB00146 Calcidiol C27H44O2 2.246575 0.077845
DB01436 Alfacalcidol C27H44O2 2.246575 0.077845
DB00154 Dihomo-Î3-linolenic acid C20H34O2 2.25 0.078451
DB00592 Piperazine C4H10N2 2.25 0.078451
DB01191 Dexfenfluramine C12H16F3N 2.25 0.078451
DB01431 Allylestrenol C21H32O 2.259259 0.080048
DB00375 Colestipol C8H23N5.C3H5ClO 2.26087 0.080319
DB00330 Ethambutol C10H24N2O2 2.263158 0.080701
DB00162 Vitamin A C20H30O 2.27451 0.082539
DB01365 Mephentermine C11H17N 2.275862 0.082751
DB01170 Guanethidine C10H22N4 2.277778 0.08305
DB00132 Alpha-Linolenic Acid C18H30O2 2.28 0.083392
DB06809 Plerixafor C28H54N8 2.288889 0.084723
DB08868 Fingolimod C19H33NO2 2.290909 0.085017
DB00858 Drostanolone C20H32O2 2.296296 0.085784
DB00136 Calcitriol C27H44O3 2.297297 0.085924
DB00910 Paricalcitol C27H44O3 2.297297 0.085924
DB00376 Trihexyphenidyl C20H31NO 2.301887 0.086554
DB01022 Phylloquinone C31H46O2 2.303797 0.086811
DB00191 Phentermine C10H15N 2.307692 0.087326
DB00313 Valproic Acid C8H16O2 2.307692 0.087326
DB01577 Methamphetamine C10H15N 2.307692 0.087326
DB06204 Tapentadol C14H23NO 2.307692 0.087326
DB06709 Methacholine C8H18NO2 2.310345 0.087669
DB08887 Icosapent ethyl C22H34O2 2.310345 0.087669
DB01187 Iophendylate C19H29IO2 2.313725 0.088098
DB01337 Pancuronium C35H60N2O4 2.316832 0.088483
DB00947 Fulvestrant C32H47F5O3S 2.318182 0.088648
DB01083 Orlistat C29H53NO5 2.318182 0.088648
DB00387 Procyclidine C19H29NO 2.32 0.088868
DB00942 Cycrimine C19H29NO 2.32 0.088868
DB08804 Nandrolone decanoate C28H44O3 2.32 0.088868
target/inspect/CHEMBL613740) (EMBL-EBI. ChEMBL). The
AQVN/EIIP descriptor values were calculated for the learning set
(Figure 1) and range for selection was based on their distribution.
AQVN descriptor values were in range 2.21–2.32 for WT and
2.21–2.44 for S31N mutant. More than 80% of the compounds of
WT inhibitors and 83% M2 S31N mutant ion channel inhibitors
from the learning set were inside the common active domain for
both while having AQVN and EIIP values within the intervals
of (2.21–2.32) and (0.071–0.089). Inside this common active
domain is also amantadine with AQVN/EIIP 2.214/0.0717. The
reported domain was selected as a criterion for the selection of
compounds representing candidate dual M2WT and S31 mutant
ion channel inhibitors (Figure 1). By applying the EIIP/AQVN-
based virtual screening criterion, 39 drugs were chosen (Table 1)
out of 2,627 approved drugs from the DrugBank (http://www.
drugbank.ca) (Wishart et al., 2006).
All 39 selected drugs were imported in Pentacle software,
protonated at pH 7.4, and aligned toward principal moment
of inertia. In ligand based virtual screening, we used centroid
distance method as criteria for similarity between learning set
and candidate compounds. Top 5 candidates from DrugBank
selection are presented in Table 2.
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TABLE 2 | Five best candidates from virtual screening, with Drugbank ID, Similarity distance, structure, and EIIP descriptor values.
Drugbank ID Name Similarity distance from centroid Structure AQVN EIIP
DB01170 Guanethidine 1.3446 2.277778 0.08305
DB00191 Phentermine 1.4234 2.307692 0.087326
DB01577 Methamphetamine 1.4334 2.307692 0.087326
DB01191 Dexfenfluramine 1.5377 2.25 0.078451
DB00942 Cycrimine 1.6057 2.32 0.088868
TABLE 3 | Docking energies of five best candidates from virtual screening, with Drugbank ID, Docking energies, and affinity ratio.
Drugbank ID Name Docking energy on WT M2
channel (kcal/mol)
Docking energy on S31N
mutant M2 channel (kcal/mol)
Affinity ratio
WT:S31N*
DB00942 Cycrimine −8.3 −8.3 1
DB01191 Dexfenfluramine −6.3 −6.0 0.6
DB01170 Guanethidine −5.9 −5.7 0.71
DB00191 Phentermine −5.3 −4.8 0.43









We further carried out molecular docking of five candidates
to both the wild type M2 channel and S31N mutant channel.
The docking energies obtained are presented in Table 3.
The candidate with the lowest binding energy and equal
affinity to both WT channel and S31N mutant channel
was cycrimine, with docking energy −8.3 kcal/mol. Docked
conformations of cycrimine are presented on Figures 1, 2. In
both WT and S31N mutant of M2 channel, cycrimine conserves
corresponding intermolecular receptor-ligand interactions, Ala
30 and Ser 31 in case of WT and Asn 31 in the case
of the S31N mutant. As presented on Figures 2, 3, the
orientation of cycrimine, compared to crystal coordinates of
amandatine and M2WJ332 show cycrimine’s ability to form
hydrogen bond interactions with Ser 31 i.e., Asn 31, while
keeping hydrophobic interactions with Ala 30. This could be
a possible explanation as to why cycrimine shows relatively
high and equal affinity to both WT and S31N mutant
M2 channels (−8.3 kcal/mol, or 800 nM). Other compounds
show similar binding patterns as cycrimine; however, in most
other cases the affinity ratio is in favor of the WT M2
channel protein.
In order to validate our in silico screening approach,
we examined the antiviral activity of guanethidine, the top
candidate from the DrugBank selection (Table 2), in vitro. As
a positive control, influenza virus was premixed with 10 uM
of merimepodib, an IMPDH inhibitor with known antiviral
activity against a variety of viruses including influenza (Markland
et al., 2000; Tong et al., 2018). Addition of guanethidine
to cells infected with 2009 H1N1 pandemic influenza virus
resulted in significantly lower viral titers in a dose-dependent
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FIGURE 2 | Best-ranking docked conformation of Cycrimine (gray carbon
atoms) in solid state NMR structure of WT M2 channel (PDB 2KQT), compared
to amantadine coordinates in complex (green carbon atoms).
FIGURE 3 | Best-ranking docked conformation of Cycrimine (gray carbon
atoms) in solid state NMR structure of S31N mutant M2 channel (PDB 2LY0),
compared to drug M2WJ332 coordinates in complex (green carbon atoms).
manner. Both 100 and 10µM guanethidine treatment resulted
in significant reductions in viral titers at day 1 post-infection,
with 100µM of guanethidine producing a 1–2 log reduction in
viral titers.
DISCUSSION
Current prevention and treatment options for influenza A
and B infections are insufficient due to increased clinical use
of licensed antivirals leading to the emergence of resistant
viral strains (Hayden and de Jong, 2011). In a quest for
new preventive and therapeutic options to minimize drug
resistance and threats of outbreaks of pandemic viruses,
the main obstacle is the fact that drug development is an
expensive, time-consuming, and risky enterprise. Therefore,
drug repurposing represents a promising therapeutic strategy
for many viral diseases including anti-influenza A and B
treatment. Various predictive computational approaches have
been developed to identify drug repositioning opportunities
against influenza viruses (Sencanski et al., 2015). Previously,
the EIIP/AQVN criterion has been proven to be an efficient
filter in virtual screening of molecular libraries for candidate
inhibitors of HIV and Ebola virus infection (Tintori et al.,
2007; Veljkovic et al., 2015a,b). Using this approach, ibuprofen
was selected as an inhibitor of the Ebola virus infection, and
this prediction was later experimentally confirmed (Zhao et al.,
2016; Paessler et al., 2018.)
To select drug candidates for M2 inhibitors, the virtual
screening protocol in our study was based on the application of
successive filters. The previous study of EIIP/AQVN distribution
of compounds from the PubChem database (http://www.ncbi.
nlm.nih.gov/pccompound) showed that 92.5% compounds from
PubChem are homogenously distributed inside EIIP and AQVN
intervals (0.00–0.11 Ry) and (2.4–3.3), respectively (Veljkovic
et al., 2011). The domain that encompasses themajority of known
chemical compounds was designated as a “basic EIIP/AQVN
chemical space” (BCS). Results of the application of VS based
on the EIIP/AQVN filter in this study showed that the active
group of candidate M2 inhibitors is very specific, belonging
to the sparse cluster of compounds that are out of BCS. This
finding indicates that testing only a minor fraction of the
compounds from the active EIIP/AQVN domain has a greater
chance to inhibit M2 function than compounds with any other
EIIP/AQVN values. The proposed AQVN/EIIP interval for the
selection of dual M2 inhibitor candidates encompasses only
3% of all chemical molecules. It is therefore not surprising
that the previous results from the high-throughput screening
had a 10- to 100-fold lower hit rate compared to screens for
other targets (Balgi et al., 2013). These results confirm that
the M2 is a challenging target for selective inhibition and
drug development. In the course of further analysis in our
study, the next following two filters were applied in selection
of candidates with dual inhibition against M2 WT and M2
S31N mutant protein. First, by applying ligand based virtual
screening, the candidates were selected using lowest distance
from centroid in the PCA model. This model was based on
variables constructed from MIF descriptors of compounds from
the learning set. Therefore, their pharmacophore similarity was
criteria for the selection. Structure-based approach, as the next
step, allows the docking of selected compounds from the first
step into both crystal structures of M2 WT and S31N mutant
proteins. In this step, the output docking energies (binding free
energies) were used as criteria to rank the candidates. In order to
address candidate compounds in more detail, the affinity ratio
was also calculated. Two of the best candidates are presented
in Figures 2, 3, and in Tables 2, 3. The biological significance
of docking energy is to select the best candidate that targets
both the WT and S31N mutant form of M2. i.e., a dual target
candidate. We carried out docking energy comparisons for all
candidates, and calculated their ratio with prior conversion to
Ki values (docking energy has logarithmic dependency of Ki).
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FIGURE 4 | Influenza A/CA/07/2009 (H1N1) viral titers at 0, 1, and 2 days post-infection (dpi) after treatment with the indicated drug concentrations. Ten micromolar
(10µM) merimepodib was used as a positive control. Results are plotted as the means of triplicate observations, with standard deviations shown. Significant decrease
in viral load is marked by asterisk.
Ratio of equilibrium constants between two equilibrium systems
(in our case, WT and S31N mutant M2 receptors) that share
same ligand in the same environment gives information about
that ligand’s preference to a certain receptor type. The closer
the value of Ki ratio is to 1, the more the ligand is prone to
target both receptor types equally and therefore, the ligand is
a better dual target candidate. It should also be emphasized
that it was assumed that the selected dual inhibitors targeting
both M2 proteins might have advantages over mono inhibitors.
This is reflected in a higher genetic barrier that enables dual
inhibitors to preserve activity if the mutant reverts back to WT
sequence (Ma et al., 2016; Wang, 2016).
We selected guanethidine as the best ranked
compound from ligand-based virtual screening for further
experimental validation. In the experiments with influenza
A/CA/07/2009 (H1N1) it was shown that guanethidine
inhibits influenza virus production (Figure 4) in a
dose-dependent manner.
Another of the best ranked inhibitors from our computational
study, methamphetamine, has actually documented good
inhibitory activity against influenza A (Chen et al., 2012). It
was previously demonstrated that methamphetamine inhibits
influenza A virus replication in vitro primarily via acting
at the viral replication stage in which M2 plays a major
role. Another drug among the best ranked candidates for
repurposing against M2 is cycrimine, a drug used to reduce
levels of acetylcholine to balance levels of dopamine in the
treatment of Parkinson’s disease (Kafer and Poch, 1957; Fahn,
2015). Interestingly, the anti-influenza drug amantadine,
previously repurposed for treatment of Parkinson’s disease,
also causes anticholinergic-like side effects (Horstink et al.,
2006). In addition, as amantadine and cycrimine are in the same
EIIP/AQVN domain, it can be expected from previous studies
that they share same therapeutic targets. Other drugs selected as
potential M2 inhibitors are ergocalciferol, calcidiol, alfacalcidol.
This result is very interesting as vitamin D metabolites were
previously connected to potential anti-influenza activity
(Gruber-Bzura, 2018). Another FDA approved drug with
documented anti-influenza properties, Alpha-Linolenic Acid,
was also selected as a potential M2 inhibitor in our study,
indicating the usefulness of the proposed screen (Bai et al.,
2012).
In conclusion, the results presented here suggest that
guanethidine represents a promising molecular template for
further development of drugs against influenza virus. Other
selected drugs from our computational study present valuable
starting points for further experimental investigations in
a quest for safe, new treatments for human and animal
influenza infections.
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